Gilead Sciences press release
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs.
This novel HIV treatment pairs bictegravir, a global guideline-recommended integrase strand transfer inhibitor (INSTI) with a high barrier to resistance, with lenacapavir, a first-in-class capsid inhibitor that has a novel mechanism of action with no cross-resistance to other antiretrovirals.
Bixlenvo requires a two-day initiation dose with Sunlenca® (lenacapavir), thereafter only Bixlenvo is taken orally once a day.
Read the full press release here.
Source : Gilead Sciences
Related HIV and Co-Infections News
-
[Press release] FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children
-
Contagion Live: Redefining HIV management: Emerging antiretroviral drug classes and immunologic strategies shaping the future of HIV treatment, prevention
-
Infectious Disease Advisor: Real-world data on BIC/FTC/TAF switch and long-acting ART in patients with viremia
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.